NCT01165216View on ClinicalTrials.gov

Japanese Study of Ipilimumab Administered in Combination With Paclitaxel/Carboplatin in Patients With Nonsmall-cell Lung Cancer

PHASE1CompletedINTERVENTIONAL
Enrollment

15

Participants

Timeline

Start Date

September 30, 2010

Primary Completion Date

June 30, 2013

Study Completion Date

June 30, 2013

Conditions
Non-Small Cell Lung Cancer
Interventions
DRUG

Ipilimumab, 3 mg

Intervenous (IV) injection, administered every 3 weeks for up to 6 cycles

DRUG

Ipilimumab, 10 mg

IV injection, administered every 3 weeks for up to 6 cycles

DRUG

Paclitaxel

IV injection, 175 mg/m\^2, administered every 3 weeks for up to 6 cycles

DRUG

Carboplatin

IV injection, AUC=6, administered every 3 weeks for up to 6 cycles. (AUC=area under the concentration curve)

Trial Locations (1)

1040045

Local Institution, Chuo-ku

Sponsors
All Listed Sponsors
lead

Bristol-Myers Squibb

INDUSTRY